To experimentally examine the patient data-driven hypothesis of ALK pathway involvement in CMS1 colon cancer subtype, we treated CMS1 (LoVo and SW48), CMS2 (LS1034 and NCIH508), CMS3 (HT29 and LS174T) and CMS4 (HCT116 and Caco-2) cell lines with increasing concentrations of CZB or ALC. Here, ALK is linked to malignant colon neoplasm.